Aridis Pharmaceuticals (NASDAQ:ARDS) Lifted to “Buy” at ValuEngine

ValuEngine upgraded shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a hold rating to a buy rating in a research note published on Thursday morning, ValuEngine reports.

Several other equities analysts have also recently weighed in on the company. Northland Securities restated a buy rating and set a $40.00 price objective on shares of Aridis Pharmaceuticals in a research note on Tuesday, July 30th. Zacks Investment Research upgraded Aridis Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, July 16th. Finally, Maxim Group restated a buy rating on shares of Aridis Pharmaceuticals in a research note on Wednesday. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Aridis Pharmaceuticals has an average rating of Buy and an average target price of $27.50.

NASDAQ:ARDS traded up $0.65 during trading hours on Thursday, hitting $8.45. 283 shares of the company traded hands, compared to its average volume of 3,822. The business’s 50-day simple moving average is $9.71. Aridis Pharmaceuticals has a one year low of $6.91 and a one year high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.12). Aridis Pharmaceuticals had a negative net margin of 660.78% and a negative return on equity of 1,961.31%. The company had revenue of $1.02 million for the quarter. Equities research analysts forecast that Aridis Pharmaceuticals will post -3.11 earnings per share for the current year.

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Featured Article: What is meant by holder of record?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aridis Pharmaceuticals (NASDAQ:ARDS)

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with's FREE daily email newsletter.